Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $81.6667.

Several brokerages recently issued reports on ARWR. Chardan Capital upped their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Bank of America boosted their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Royal Bank Of Canada upped their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. The Goldman Sachs Group increased their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total value of $641,900.00. Following the transaction, the insider directly owned 236,958 shares in the company, valued at approximately $15,210,334.02. This trade represents a 4.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Large investors have recently made changes to their positions in the company. Marex Group plc bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $576,000. Nordea Investment Management AB grew its position in shares of Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after buying an additional 158,937 shares during the period. Marshall Wace LLP raised its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after buying an additional 2,096,238 shares during the last quarter. HBK Sorce Advisory LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $2,823,000. Finally, Erste Asset Management GmbH lifted its holdings in Arrowhead Pharmaceuticals by 55.3% in the third quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock valued at $2,466,000 after buying an additional 26,000 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $61.03 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The company has a market cap of $8.55 billion, a price-to-earnings ratio of 39.89 and a beta of 1.26. The stock has a fifty day moving average price of $62.31 and a two-hundred day moving average price of $54.91. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. During the same quarter in the previous year, the company posted ($1.39) EPS. Arrowhead Pharmaceuticals’s revenue for the quarter was up 10461.3% on a year-over-year basis. Analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.